[ CAS No. 1813-33-8 ] {[proInfo.proName]}

Name: 1813-33-8|2-Chloro-4-(trifluoromethyl)benzonitrile|98%
Brand: Ambeed
SKU: A247204
Price: 14.0 USD
Availability: InStock
Rating: 93 (29 reviews)

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

2D 3D

Structure of 1813-33-8 * Storage: {[proInfo.prStorage]}

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

For Research Only 110K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 1813-33-8 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 1813-33-8 ]

SDS Specification

Alternatived Products of [ 1813-33-8 ]

Product Details of [ 1813-33-8 ]

CAS No. :	1813-33-8	MDL No. :	MFCD00084939
Formula :	C₈H₃ClF₃N	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	GEHMLBFNZKJDQM-UHFFFAOYSA-N
M.W :	205.56	Pubchem ID :	2736476
Synonyms :

Calculated chemistry of [ 1813-33-8 ]

Physicochemical Properties

Num. heavy atoms :	13
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.12
Num. rotatable bonds :	1
Num. H-bond acceptors :	4.0
Num. H-bond donors :	0.0
Molar Refractivity :	41.17
TPSA :	23.79 Å²

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	Yes
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-5.32 cm/s

Lipophilicity

Log Po/w (iLOGP) :	1.97
Log Po/w (XLOGP3) :	3.15
Log Po/w (WLOGP) :	4.38
Log Po/w (MLOGP) :	3.08
Log Po/w (SILICOS-IT) :	3.46
Consensus Log Po/w :	3.21

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	1.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-3.37
Solubility :	0.0868 mg/ml ; 0.000422 mol/l
Class :	Soluble
Log S (Ali) :	-3.32
Solubility :	0.0985 mg/ml ; 0.000479 mol/l
Class :	Soluble
Log S (SILICOS-IT) :	-3.99
Solubility :	0.0209 mg/ml ; 0.000102 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.8

Safety of [ 1813-33-8 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P280-P305+P351+P338-P310	UN#:	N/A
Hazard Statements:	H302-H315-H319-H332-H335	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 1813-33-8 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 1813-33-8 ]
Downstream synthetic route of [ 1813-33-8 ]

[ 1813-33-8 ] Synthesis Path-Upstream 1~2

1
[ 773837-37-9 ]
[ 78068-85-6 ]
[ 1813-33-8 ]

Reference： [1] Patent: CN107540583, 2018, A, . Location in patent: Paragraph 0035-0037

2
[ 1813-33-8 ]
[ 82096-91-1 ]

Yield	Reaction Conditions	Operation in experiment
78.8%	Stage #1: With diisobutylaluminium hydride In toluene at -78℃; Inert atmosphere Stage #2: With acetic acid In water; toluene at 0℃; for 2 h;	2-Chloro-4-(trifluoromethyl)benzonitrile (500 mg, 2.43 mmol) was diluted with toluene (3 mL), placed under nitrogen and cooled to -78°C. DIBAL-H (4865 μL, 4.86 mmol) was added dropwise and the reaction was stirred for 1 hour. The reaction was warmed to 0⁰C and acetic acid (2 mL) was added followed by 10 mL of water. After stirring for 2 hours, the reaction was extracted twice with ethyl acetate, washed with Rochelle's salt, dried over MgSO₄, filtered and concentrated. The material was purified using a biotage 25 cartridge running a gradient, 100percenthexanes to 20percentDCM/hexanes to yield 2-chloro-4-(trifluoromethyl)benzaldehyde (400 mg, 1.92 mmol, 78.8 percent yield) as a clear oil.
30%	Stage #1: With diisobutylaluminium hydride In toluene for 0.5 h; Cooling with ethanol-dry ice Stage #2: With acetic acid In water; toluene at 20℃; for 2 h;	Dissolve 2-chloro-4-trifluoromethylbenzonitrile (405 mg, 1.97 mmol) in anhydrous toluene (7 mL) and cool in a dry ice/ethanol bath. Add diisobutylaluminum EPO <DP n="62"/>hydride (DIBAL) (3.94 niL, 3.94 mmol, 1.0 M in toluene) slowly. Stir 30 min. Warm to room temperature, add acetic acid (2 mL) and water (10 rnL) and stir for 2 hours. Extract the aqueous layer with ethyl acetate twice. Wash the organic layer with potassium sodium tartrate solution (Rochelle salt) twice. Dry (magnesium sulfate), filter, and concentrate to give a residue. Chromatograph the residue on silica gel eluting with a gradient of 100:0 to 1:1 hexanes:dichloromethane to give 2-chloro-4- trifluoromethylbenzaldehyde (123 mg, 30percent). ¹H NMR (400 MHz, CDCl₃) δ 10.52 (s, IH), 8.05 (d, IH₅ J = 8.0 Hz), 7.75 (s, IH), 7.66 (d, IH, J = 8.0 Hz).

Reference： [1] Patent: WO2009/158426, 2009, A1, . Location in patent: Page/Page column 139
[2] Patent: WO2006/44454, 2006, A1, . Location in patent: Page/Page column 60-61

[ 1813-33-8 ] Synthesis Path-Downstream 1~88

1
[ 917-92-0 ]
[ 1813-33-8 ]
[ 1008529-50-7 ]

Yield	Reaction Conditions	Operation in experiment
	With triethylamine;tris(dibenzylideneacetone)dipalladium(0) chloroform complex; copper(l) iodide; DavePhos; at 65℃; for 2h;	Example IA. 2-(3.3 -dimethylbut-1-ynyl)-4-(trifluoromethyl)benzonitrile .Pd2dba3:CHCl3 (0.439 g, 0.424 mmol, 1.5%), dicyclohexylphosrhohino-2'-(N,N- dimethylamino)biphenyl (0.640 g, 1.63 mmol, 6%), and CuI (0.155 g, 0.816 mmol, 3%) were placed in a flask and purged with N2. triethylamine (16 mL) was added and the mixture was stirred for 5 minutes followed by the addition of <strong>[1813-33-8]3-chloro-4-cyanobenzotrifluoride</strong> (4.00 mL, 27.0 mmol) and 3,3-dimethylbutyne (4.00 mmol, 1.2 eq). The mixture was heated under N2 at 65 0C for 2 hours, cooled to ambient temperature and diluted with ethyl acetate (~300 mL). The mixture was washed sequentially with ~2% aqueous NH4OH (120 mL) and saturated aqueous NH4CI (10OmL). The organic layer was dried (Na2SO4), filtered, concentrated, and filtered through SiO2 (~90 mL) with 4% diethyl ether/Hex to provide the title compound. 1H- NMR (CDCl3) delta 7.71-7.75 (m, 2H), 7.58 (dd, IH), 1.37 (s, 9H).
	With copper(l) iodide; triethylamine;tris-(dibenzylideneacetone)dipalladium(0); DavePhos; at 65℃; for 4h;Inert atmosphere;	To a flask was added Pd2dba3 (0.405 g), DavePhos (0.6884 g, 1.75 mmol), and CuI (0.1655 g). This was purged with nitrogen and degassed; triethylamine (100 mL) was then added. <n="43"/>Benzonitrile (XVII) (36.2 g, 176 mmol) was then added, and the mixture was heated to 65 0C. 3,3-dimethylbutyne (23.7 g, 288 mmol) was then slowly added over 2 hours. The mixture was heated an additional 2 hours, and the heat removed. The mixture was diluted with isopropyl acetate (150 mL) and washed twice with water (150 mL) and twice with 10% aqueous citric acid (150 mL). The organics were diluted with methanol (40 mL), and the volume reduced in vacuo to 60 mL. This was repeated twice with 190 mL methanol, the residual material diluted to 250 g with methanol and used in the next step as a solution. An analytical sample was obtained by removing all the solvent in vacuo.1H NMR (CDCl3, 400 mHz) 7.75 - 7.70 (m, 2H), 7.60-7.55 (m, IH), 1.37 (s, 9H); 13C NMR (CDCl3, 100MHz) 132.6, 128.7, 128.6, 123.8, 123.7, 116.24, 107.96, 75.06, 30.73, 28.64.

Reference： [1]Journal of Organic Chemistry,2009,vol. 74,p. 9539 - 9542
[2]Patent: WO2008/24945,2008,A1 .Location in patent: Page/Page column 26-27
[3]Bioorganic and Medicinal Chemistry Letters,2010,vol. 20,p. 3291 - 3294
[4]Patent: WO2009/117626,2009,A2 .Location in patent: Page/Page column 41-42

2
[ 1813-33-8 ]
(2-isobutyl-4-(trifluoromethyl)phenyl)methanamine [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
		Example 2A. (2-isobutyl-4-(trifluoromethyl)phenyl)methanamine. A solution of 2-methylpropenylmagnesium bromide (0.5 M in THF, 6.0 mL, 3.0 mmol) was added to a solution of ZnCh (1 -0 M in diethyl ether, 3.0 mL, 3.0 mmol) at 00C. The mixture was stirred for 10 minutes cold, and an additional 30 min after removing the cooling bath. 2-chloro-4-trifluoromethyI-benzonitrile (0.35mL, 2.4 mmol) was added, followed by a solution containing Pd2dba3.CHCl3 (48.5 mg, 0.047 mmol) and 2- dicyclohexylphophino-2'-(N,N-dimethylamino)biphenyl (56.3 mg, 0.14 mmol) in THF (1 mL). The mixture was stirred at 60 0C for 3 hours, diluted with ethyl acetate and the resulting mixture washed sequentially with 0.1 N aqueous HCl (2x) and brine (Ix). The organic layer was dried (Na2SO4), filtered and concentrated under reduced pressure, and purified by flash chromatography (5% diethyl ether/hexane) to provide 0.264 g of the nitrile as a clear oil which was used without further purification. The oil was dissolved in 4:1 methanol: ethyl acetate (25 mL), shaken in the presence of 10% Pd/C and Ra Ni (catalytic amounts) under H2 (60 psi) overnight. The mixture was filtered and concentrated under reduced pressure, and the residue purified by flash chromatography (20-100% ethyl acetate in dichloromethane as a gradient elution) to provide the title compound. 1H NMR (CDCl3) delta 7.43-7.52 (m, 2H), 7.37 (brs, IH), 3.94 (brs, 2H), 2.57 (d, 2H), 1.87 (m, IH), 1.49 (brs, 2H), 0.94 (d, 6H).

Reference： [1]Patent: WO2008/24945,2008,A1 .Location in patent: Page/Page column 28

3
[ 1813-33-8 ]
[ 625-81-0 ]
[ 1008529-54-1 ]

Yield	Reaction Conditions	Operation in experiment
	(1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; In 1,4-dioxane; toluene; for 18h;Heating / reflux;	Example 4A. 2-isopropyl-4-(trifluoromethyl)benzonitrile. To a solution of <strong>[1813-33-8]2-chloro-4-trifluoromethyl-benzonitril</strong>e (0.67mL, 4.5 mmol) and [1,1 '-bisfdiphenylphosphinojferroceneldichloropalladiumtll) (110 mg, 0.14 mmol) in 15 mL of dioxane was added Zn(iso-Propyl)2 (IN in toluene, 9 mmol). The mixture was heated to reflux for 18 hours, cooled to ambient temperature and diluted with methanol. The mixture was further diluted with ether and washed sequentially with IN HCl, water and brine. The organic layer was dried over Na2SO4, filtered, and then concentrated under reduced pressure. The crude product was purified by flash column chromatography (0% to 10% ethyl acetate/hexane) to provide the title compound. 1H NMR (CDCl3) delta 7.73 (d, IH), 7.63 (s, IH), 7.55 (d, IH), 3.45 (sept, IH), 1.36 (d, 6H).

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2010,vol. 20,p. 3291 - 3294
[2]Patent: WO2008/24945,2008,A1 .Location in patent: Page/Page column 31

4
[ 288-32-4 ]
[ 1813-33-8 ]
[ 25373-51-7 ]

Reference： [1]Synthetic Communications,2008,vol. 38,p. 626 - 636

5
[ 1813-33-8 ]
[ 581813-20-9 ]

Yield	Reaction Conditions	Operation in experiment
		EXAMPLE 246A 2-chloro-4-(trifluoromethyl)benzylamine The title compound was prepared using the procedure described in Example 244A using <strong>[1813-33-8]2-chloro-4-(trifluoromethyl)benzonitrile</strong> instead of 4-bromo-3-methylbenzonitrile. MS (ESI+) m/z 209 (M+H)+; 1H NMR (DMSO, 300 MHz) delta 3.97 (s, 2H), 7.50-7.70 (m, 3H).
		Example 246A 2-chloro-4-(trifluoromethyl)benzylamine The title compound was prepared using the procedure described in Example 244A using <strong>[1813-33-8]2-chloro-4-(trifluoromethyl)benzonitrile</strong> instead of 4-bromo-3-methylbenzonitrile. MS (ESI+) m/z 209 (M+H)+; 1H NMR (DMSO, 300 MHz) delta 3.97 (s, 2H), 7.50-7.70 (m, 3H).

Reference： [1]Patent: WO2004/39764,2004,A1 .Location in patent: Page/Page column 183-184
[2]Patent: US6933311,2005,B2
[3]Patent: US2004/157849,2004,A1

6
[ 928-51-8 ]
[ 1813-33-8 ]
[ 131084-28-1 ]

Yield	Reaction Conditions	Operation in experiment
	With hydrogenchloride; In tetrahydrofuran; tetrahydrofuran, ethyl bromide;	EXAMPLE 17 1'-[4-[1-(4-Fluorophenyl)-5-trifluoromethylindazol-3-yl]-1-butyl]spiro]isobenzofuran-1(3H),4'-piperidine], 17a. To a suspension of magnesium turnings (135 g) in 300 ml of dry tetrahydrofuran, ethyl bromide (140 g) dissolved in 500 ml of dry tetrahydrofuran was slowly added followed by reflux for 20 min. A solution of 4-chloro-1-butanol (274 g) in 500 ml of tetrahydrofuran was added dropwise at reflux temperature. After stirring for 20 min, the Grignard solution was filtered and added portionwise to a solution of <strong>[1813-33-8]2-chloro-4-trifluoromethyl-benzonitril</strong> (200 g) in 600 ml of dry tetrahydrofuran. The reaction mixture was stirred for 16 h at room temperature followed by addition af 2N hydrochloric acid and ice. Extraction with ether, drying of the ether phase over magnesium sulfate and removal of solvent in vacuo left a viscous oil which was applied to a silica gel column (eluent:dichloromethane/ether=3:1) giving 4-(2-chloro-5-trifluoromethylbenzoyl)-1-butanol (101 g) as an oil.

Reference： [1]Patent: US5665725,1997,A

7
[ 1813-33-8 ]
[ 82096-91-1 ]

Yield	Reaction Conditions	Operation in experiment
78.8%		2-Chloro-4-(trifluoromethyl)benzonitrile (500 mg, 2.43 mmol) was diluted with toluene (3 mL), placed under nitrogen and cooled to -78C. DIBAL-H (4865 muL, 4.86 mmol) was added dropwise and the reaction was stirred for 1 hour. The reaction was warmed to 00C and acetic acid (2 mL) was added followed by 10 mL of water. After stirring for 2 hours, the reaction was extracted twice with ethyl acetate, washed with Rochelle's salt, dried over MgSO4, filtered and concentrated. The material was purified using a biotage 25 cartridge running a gradient, 100%hexanes to 20%DCM/hexanes to yield 2-chloro-4-(trifluoromethyl)benzaldehyde (400 mg, 1.92 mmol, 78.8 % yield) as a clear oil.
30%		Dissolve <strong>[1813-33-8]2-chloro-4-trifluoromethylbenzonitrile</strong> (405 mg, 1.97 mmol) in anhydrous toluene (7 mL) and cool in a dry ice/ethanol bath. Add diisobutylaluminum EPO <DP n="62"/>hydride (DIBAL) (3.94 niL, 3.94 mmol, 1.0 M in toluene) slowly. Stir 30 min. Warm to room temperature, add acetic acid (2 mL) and water (10 rnL) and stir for 2 hours. Extract the aqueous layer with ethyl acetate twice. Wash the organic layer with potassium sodium tartrate solution (Rochelle salt) twice. Dry (magnesium sulfate), filter, and concentrate to give a residue. Chromatograph the residue on silica gel eluting with a gradient of 100:0 to 1:1 hexanes:dichloromethane to give 2-chloro-4- trifluoromethylbenzaldehyde (123 mg, 30%). 1H NMR (400 MHz, CDCl3) delta 10.52 (s, IH), 8.05 (d, IH5 J = 8.0 Hz), 7.75 (s, IH), 7.66 (d, IH, J = 8.0 Hz).

Reference： [1]Patent: WO2009/158426,2009,A1 .Location in patent: Page/Page column 139
[2]Patent: WO2006/44454,2006,A1 .Location in patent: Page/Page column 60-61

8
[ 1813-33-8 ]
[ 53731-17-2 ]
C₁₃H₉F₄N [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2010,vol. 20,p. 3291 - 3294

9
[ 1813-33-8 ]
[ 536-74-3 ]
2-(phenylethynyl)-4-(trifluoromethyl)benzonitrile [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2010,vol. 20,p. 3291 - 3294

10
[ 1813-33-8 ]
[ 627-41-8 ]
C₁₂H₈F₃NO [ No CAS ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2010,vol. 20,p. 3291 - 3294

11
[ 1813-33-8 ]
[ 108-95-2 ]
[ 155256-33-0 ]

Reference： [1]Bioorganic and Medicinal Chemistry Letters,2010,vol. 20,p. 3291 - 3294

12
[ 110-89-4 ]
[ 1813-33-8 ]
[ 689141-78-4 ]

Yield	Reaction Conditions	Operation in experiment
56%	at 80℃;	To commercially available <strong>[1813-33-8]2-chloro-4-trifluoromethylbenzonitrile</strong> 13 (1 ml, 7.2 mmol) was added piperidine (4equiv., 2.8ml) and the solution was heated at 80C overnight. The reaction was evaporated and the residue was dissolved in AcOEt and washed with water and brine. The organic phase was evaporated obtaining 1 g of a yellow oil. Yield = 56% 'HNMR (DMSO, 200 MHz) delta 1.60 (6H, m), 3.20 (4H, m), 7.34 (2H, m), 7.89 (1H, dd, J = 8.6 Hz, J' = 0.4 Hz)
56%	at 80℃;	Preparation of 4-(trifluoromethyl)-2-(piperidin-1-yl)benzonitrile 14c (scheme 7) To commercially available 2-chloro-4-benzonitrile (1 ml, 7.2 mmol) was added piperidine (4equiv., 2.8ml) and the solution was heated at 80C overnight. The reaction was evaporated and the residue was dissolved in AcOEt and washed with water and brine. The organic phase was evaporated obtaining 1 g of a yellow oil. Yield = 56% 1HNMR (DMSO, 200 MHz) delta 1.60 (6H, m), 3.20 (4H, m), 7.34 (2H, m), 7.89 (1H, dd, J = 8.6 Hz, J' = 0.4 Hz)
	With 1,8-diazabicyclo[5.4.0]undec-7-ene; In 1,4-dioxane; at 50℃; for 12h;	General procedure: A mixture of 2-chloro-4-(trifluoromethyl)-benzonitrile (1.00 mmol), appropriate amine (NR2, 2.00 mmol),and DBU (2.5 mmol) were dissolved in 1,4-dioxane (8 ml). Themixture was stirred for 12 h at 50 C. The reaction was quenched with water and extracted with EtOAc twice. The combined organicextracts were dried over MgSO4, filtered, and concentrated invacuo. The residue was purified by flash column chromatographyon silica gel using EtOAc/hexane (1:7-1:10) eluant condition.(NR2 = 4-(4-fluorophenyl)-1,2,3,6-tetrahydropyridine hydrochloridefor 17).

Reference： [1]Patent: WO2011/120604,2011,A1 .Location in patent: Page/Page column 32; 133
[2]Patent: EP2377850,2011,A1 .Location in patent: Page/Page column 13
[3]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 6844 - 6854

13
[ 110-91-8 ]
[ 1813-33-8 ]
[ 935517-10-5 ]

Yield	Reaction Conditions	Operation in experiment
83%	at 80℃;	To commercially available <strong>[1813-33-8]2-chloro-4-trifluoromethylbenzonitrile</strong> 13 (4 ml, 29 mmol) morpholine (4equiv., 10 ml) was added and the solution was heated at 80C overnight. The reaction was evaporated and the residue was dissolved in AcOEt and washed with water and brine. The organic phase was evaporated obtaining 6.19 g of a yellow oil. Yield = 83% 'HNMR (DMSO, 200 MHz) delta 3.24 (4H, m), 3.75 (4H, m), 7.94 (1H, m), 8.23 (1H, m).
83%	at 80℃;	Preparation of 4-(trifluoromethyl)-2-morpholinobenzonitrile 14d (scheme 7) To commercially available 2-chloro-4-benzonitrile (4 ml, 29 mmol) morpholine (4equiv., 10 ml) was added and the solution was heated at 80C overnight. The reaction was evaporated and the residue was dissolved in AcOEt and washed with water and brine. The organic phase was evaporated obtaining 6.19 g of a yellow oil. Yield = 83% 1HNMR (DMSO, 200 MHz) delta 3.24 (4H, m), 3.75 (4H, m), 7.94 (1H, m), 8.23 (1H, m).
	In N,N-dimethyl-formamide; at 120℃; for 6h;	General procedure: A mixture of 2-chloro-4-(trifluoromethyl)-benzonitrile (1.00 mmol), appropriate amine (NR2, 2.00 mmol)were dissolved in DMF (8 ml). The mixture was stirred for 6 h at120 C. The reaction was quenched with water and extracted withEtOAc twice. The combined organic extracts were dried overMgSO4, filtered, and concentrated in vacuo. The residue was purifiedby flash column chromatography on silica gel using EtOAc/hexane (1:7) eluant condition.

Reference： [1]Patent: WO2011/120604,2011,A1 .Location in patent: Page/Page column 33; 34; 133
[2]Patent: EP2377850,2011,A1 .Location in patent: Page/Page column 14
[3]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 6844 - 6854

14
[ 123-75-1 ]
[ 1813-33-8 ]
[ 935517-11-6 ]

Yield	Reaction Conditions	Operation in experiment
54%	at 80℃;	To commercially available <strong>[1813-33-8]2-chloro-4-trifluoromethylbenzonitrile</strong> 13 (lml, 7.2 mmol) pyrrolidine (4equiv., 2.38 ml) was added and the solution was heated at 80C overnight. The reaction was evaporated and the residue was dissolved in AcOEt and washed with water and brine. The organic phase was evaporated obtaining 940mg of a yellow solid. Yield = 54% 'HNMR (DMSO, 200 MHz) delta 1.95 (4H, m), 3.58 (4H, m), 6.94 (2H, m), 7.73 (1H, dd, J = 8 Hz, J'= 0.8 Hz).
54%	at 80℃;	Preparation of 4-(trifluoromethyl)-2-(pyrrolidin-1-yl)benzonitrile 14b (scheme 8) To commercially available 2-chloro-4-benzonitrile (1ml, 7.2 mmol) pyrrolidine (4equiv., 2.38 ml) was added and the solution was heated at 80C overnight. The reaction was evaporated and the residue was dissolved in AcOEt and washed with water and brine. The organic phase was evaporated obtaining 940mg of a yellow solid. Yield = 54% 1HNMR (DMSO, 200 MHz) delta 1.95 (4H, m), 3.58 (4H, m), 6.94 (2H, m), 7.73 (1H, dd, J = 8 Hz, J' = 0.8 Hz)
	With 1,8-diazabicyclo[5.4.0]undec-7-ene; In 1,4-dioxane; at 50℃; for 12h;	General procedure: A mixture of 2-chloro-4-(trifluoromethyl)-benzonitrile (1.00 mmol), appropriate amine (NR2, 2.00 mmol),and DBU (2.5 mmol) were dissolved in 1,4-dioxane (8 ml). Themixture was stirred for 12 h at 50 C. The reaction was quenched with water and extracted with EtOAc twice. The combined organicextracts were dried over MgSO4, filtered, and concentrated invacuo. The residue was purified by flash column chromatographyon silica gel using EtOAc/hexane (1:7-1:10) eluant condition.(NR2 = 4-(4-fluorophenyl)-1,2,3,6-tetrahydropyridine hydrochloridefor 17).

Reference： [1]Patent: WO2011/120604,2011,A1 .Location in patent: Page/Page column 30; 31; 133
[2]Patent: EP2377850,2011,A1 .Location in patent: Page/Page column 13
[3]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 6844 - 6854

15
[ 1813-33-8 ]
[ 124-40-3 ]
[ 689148-14-9 ]

Yield	Reaction Conditions	Operation in experiment
94%	at 80℃;closed vessel;	To commercially available <strong>[1813-33-8]2-chloro-4-trifluoromethylbenzonitrile</strong> 13 (0.5 ml, 3.6 mmol) dimethylamine (4equiv., 0.95 ml) was added and the solution was heated in closed vessel at 80C overnight. The reaction was evaporated and the residue was dissolved in AcOEt and washed with water and brine. The organic phase was evaporated obtaining 730 mg of a pale yellow oil. Yield = 94% 'HNMR (CDC13, 200 MHz) delta 3.13 (6H, s), 7.05 (1H, bs), 7.59 (1H, dd, J = 8.4 Hz, J' = 0.6 Hz), 7.99 (1H, bs)
94%	In ethyl acetate; at 80℃;Sealed vessel;	Example 4: 1-(2-(dimethylamino)-4-(trifluoromethyl)benzyl)-3-(2,3-dihydro-2-oxo-1H-benzo[d]imidazol-4-yl)urea (scheme 1) Preparation of 2-(dimethylamino)-4-(trifluoromethyl)benzonitrile 14a (scheme 7) To commercially available 2-chloro-4-benzonitrile (0.5 ml, 3.6 mmol) dimethylamine (4equiv., 0.95 ml) was added and the solution was heated in closed vessel at 80C overnight. The reaction was evaporated and the residue was dissolved in AcOEt and washed with water and brine. The organic phase was evaporated obtaining 730 mg of a pale yellow oil. Yield = 94% 1HNMR (CDCI3, 200 MHz) delta 3.13 (6H, s), 7.05 (1H, bs), 7.59 (1H, dd, J = 8.4 Hz, J' = 0.6 Hz), 7.99 (1H, bs)

Reference： [1]Patent: WO2011/120604,2011,A1 .Location in patent: Page/Page column 29; 133
[2]Patent: EP2377850,2011,A1 .Location in patent: Page/Page column 12

16
[ 288-32-4 ]
[ 1813-33-8 ]
[ 1338063-52-7 ]

Yield	Reaction Conditions	Operation in experiment
73%		To a suspension of NaH 60% (0.09g, 3.97 mmol) in DMF (20 mL) at 0C was added in one portion lH-imidazole (2.5 mol eq, 0.61g). After 10 min 2-chloro- 4-(trifluoromethyl)-benzonitrile (0.5 mL, 3.61 mmol) was added and the reaction mixture was heated at 100C for 2h. The reaction was cooled at room temperature, water was added and the aqueous solution was extracted with EtOAc (3x25 mL). The recombined organic phases were dried over sodium sulfate and evaporated to dryness to give the 2-imidazol-l-yl-4-(trifluoromethyl)benzonitrile as pale yellow oil (0.63g, 73% Yield) used for the reduction without further purification.

Reference： [1]Patent: WO2011/120604,2011,A1 .Location in patent: Page/Page column 125; 126

17
[ 288-88-0 ]
[ 1813-33-8 ]
[ 1338065-41-0 ]

Yield	Reaction Conditions	Operation in experiment
53%	With sodium hydride; In N,N-dimethyl-formamide; mineral oil; at 80℃;	To commercially available <strong>[1813-33-8]2-chloro-4-trifluoromethylbenzonitrile</strong> 13(lml, 7.2 mmol) in DMF 1 equiv. of NaH and 1 ,2,4-tetrazole (4equiv., 1.98 g) were added and the mixture was heated at 80C overnight. The reaction was evaporated and the residue was dissolved in AcOEt and washed with water and brine. The organic phase was evaporated obtaining 900mg of a yellow solid. Yield = 53% 'HNMR (DMSO, 200 MHz) delta 8.08 (1H, dd, J = 7.6 Hz, J' = 1 Hz), 8.33 (3H, m), 9.29 (1H, s).
53%	With sodium hydride; In N,N-dimethyl-formamide; mineral oil; at 80℃;	Preparation of 4-(trifluoromethyl)-2-(1H-1,2,4-triazol-1-yl)benzonitrile 14e (scheme7) To commercially available 2-chloro-4-benzonitrile (1ml, 7.2 mmol) in DMF 1 equiv. of NaH and 1,2,4-tetrazole (4equiv., 1.98 g) were added and the mixture was heated at 80C overnight. The reaction was evaporated and the residue was dissolved in AcOEt and washed with water and brine. The organic phase was evaporated obtaining 900mg of a yellow solid. Yield = 53% 1HNMR (DMSO, 200 MHz) delta 8.08 (1H, dd, J = 7.6 Hz, J' = 1 Hz), 8.33 (3H, m), 9.29 (1H, s).

Reference： [1]Patent: WO2011/120604,2011,A1 .Location in patent: Page/Page column 35; 133
[2]Patent: EP2377850,2011,A1 .Location in patent: Page/Page column 14

18
[ 1813-33-8 ]
[ 935518-09-5 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1
[3]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 6844 - 6854

19
[ 1813-33-8 ]
[ 935518-10-8 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1
[3]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 6844 - 6854

20
[ 1813-33-8 ]
[ 935518-11-9 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1
[3]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 6844 - 6854

21
[ 1813-33-8 ]
[ 1338064-41-7 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1
[3]Patent: EP2377850,2011,A1

22
[ 1813-33-8 ]
[ 1338065-36-3 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1

23
[ 1813-33-8 ]
[ 1338064-42-8 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1

24
[ 1813-33-8 ]
[ 1338064-43-9 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1

25
[ 1813-33-8 ]
[ 1338064-44-0 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1

26
[ 1813-33-8 ]
[ 1338064-45-1 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1

27
[ 1813-33-8 ]
[ 1338065-42-1 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1

28
[ 1813-33-8 ]
[ 1338064-67-7 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1
[3]Patent: EP2377850,2011,A1

29
[ 1813-33-8 ]
[ 1338064-68-8 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1

30
[ 1813-33-8 ]
[ 1338064-69-9 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1

31
[ 1813-33-8 ]
[ 1338064-70-2 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1

32
[ 1813-33-8 ]
[ 1338064-73-5 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1

33
[ 1813-33-8 ]
[ 1338064-74-6 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1

34
[ 1813-33-8 ]
[ 1338064-81-5 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1

35
[ 1813-33-8 ]
[ 1338064-82-6 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1
[3]Patent: EP2377850,2011,A1

36
[ 1813-33-8 ]
[ 1338064-84-8 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1
[3]Patent: EP2377850,2011,A1

37
[ 1813-33-8 ]
[ 1338064-85-9 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1
[3]Patent: EP2377850,2011,A1

38
[ 1813-33-8 ]
[ 1338064-86-0 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1

39
[ 1813-33-8 ]
[ 1338064-99-5 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1

40
[ 1813-33-8 ]
[ 1338065-00-1 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1

41
[ 1813-33-8 ]
[ 1338065-02-3 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1

42
[ 1813-33-8 ]
[ 1338065-59-0 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1

43
[ 1813-33-8 ]
[ 1338065-04-5 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1

44
[ 1813-33-8 ]
[ 1338065-60-3 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1

45
[ 1813-33-8 ]
[ 1338065-28-3 ]

Reference： [1]Patent: WO2011/120604,2011,A1

46
[ 1813-33-8 ]
[ 1338065-83-0 ]

Reference： [1]Patent: WO2011/120604,2011,A1

47
[ 1813-33-8 ]
C₁₂H₈F₃N₃O [ No CAS ]

Reference： [1]Patent: WO2011/120604,2011,A1

48
[ 1813-33-8 ]
[ 1338065-37-4 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1
[3]Patent: EP2377850,2011,A1

49
[ 1813-33-8 ]
[ 1338065-38-5 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1

50
[ 1813-33-8 ]
[ 1338065-39-6 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1

51
[ 1813-33-8 ]
[ 1338065-40-9 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1

52
[ 1813-33-8 ]
[ 1338065-43-2 ]

Reference： [1]Patent: WO2011/120604,2011,A1
[2]Patent: EP2377850,2011,A1

53
[ 1813-33-8 ]
[ 1341124-11-5 ]

Reference： [1]Patent: EP2377850,2011,A1
[2]Patent: EP2377850,2011,A1

54
[ 1813-33-8 ]
[ 1341124-12-6 ]

Reference： [1]Patent: EP2377850,2011,A1

55
[ 1813-33-8 ]
[ 1341124-13-7 ]

Reference： [1]Patent: EP2377850,2011,A1

56
[ 1813-33-8 ]
[ 55-21-0 ]
2-phenyl-7-(trifluoromethyl)quinazolin-4(3H)-one [ No CAS ]

Reference： [1]RSC Advances,2014,vol. 4,p. 44811 - 44814

57
[ 1813-33-8 ]
2-(3-fluoro-4-(methylsulfonamido)phenyl)-N-(2-(hexyloxy)-4(trifluoromethyl)benzyl)propanamide [ No CAS ]